NuCana raises $57m series B for pivotal PhIII cancer trials

Biopharmaceutical company NuCana has raised a hefty $57m in its series B financing round, for which it has ambitious plans, including collecting the pivotal Phase III data needed to bring its lead cancer candidate, Acelarin, to market.